Clinical trials: Familial Primary Pulmonary Hypertension
Pulmonary Artery Hypertension
Endothelial Cell Activation and Total Pulmonary Resistance in PAH
To determine whether changes in endothelial cell dysfunction are associated with changes in total pulmonary resistance in patients with pulmonary arterial hypertension
- Trial name
- NCT06035861
- Testing
- XBD173
- Volunteers
- 6 people
- Sponsor
- Imperial College London
Takayasu Arteritis, Pulmonary Artery Hypertension
Pulmonary Artery Involvement in Takayasu's Arteritis
The purpose of this study is to analyze the clinical manifestations, imaging features, and prognosis-related factors of pulmonary artery (PA) involvement in Takayasu's arteritis (TA), and to explore the early clinical features of…
- Trial name
- NCT03189602
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Peking Union Medical College Hospital
Hypertension, Pulmonary
Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension
OBJECTIVES: I. Provide epoprostenol (Flolan, prostaglandin I2) by chronic infusion to patients with severe primary pulmonary hypertension for whom no alternative therapy is available. II.
- Trial name
- NCT00004754
- Testing
- epoprostenol
- Sponsor
- National Center for Research Resources (NCRR)
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Pharmacogenomics in Pulmonary Arterial Hypertension
Our goal is to determine clinically in Pulmonary Arterial Hypertension patients if associations exist between the efficacy and toxicity of sitaxsentan, bosentan, and ambrisentan and several gene polymorphisms in several key…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, PAH WHO Group I
- Trial name
- NCT00593905
- Testing
- Sitaxsentan, Bosentan, Ambrisentan
- Where
- United States
- Sponsor
- West Penn Allegheny Health System
Hypertension, Pulmonary
Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients
Pulmonary arterial hypertension (PAH) involves the narrowing of blood vessels connected to and within the lungs. Focal adhesion kinase (FAK) is a focal adhesion-associated protein kinase involved in cellular adhesion and…
- Trial name
- NCT02551653
- Testing
- [11C]-GSK2256098 500 MBq
- Where
- 2 sites in United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension
Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension
In preparation for a future mechanistic study, investigators now propose to test the specific hypothesis that carnitine consumption is not reduced in PAH, that plasma carnitine levels are stable over time in PAH and that…
- Conditions
- Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension, Lung Diseases
- Trial name
- NCT04908397
- Testing
- L-carnitine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Artery Hypertension
Vascular Subphenotypes of Lung Disease in HIV & COPD
This study is looking for high blood pressure in the lungs (Pulmonary artery hypertension PAH) in HIV and COPD patients.
- Trial name
- VAST (NCT01581086)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pittsburgh
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
Hormonal, Metabolic, and Signaling Interactions in PAH
Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH
- Trial name
- NCT01884051
- Where
- United States
- Volunteers
- 1,899 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Hypertension
Genetic Research of Bone Morphogenetic Protein Receptor-II Gene in Taiwanese Patient With Primary Pulmonary Hypertension
Primary pulmonary hypertension (PPH) is a rare lung disorder in which the blood pressure in the pulmonary artery rises far above normal levels for no apparent reason.
- Trial name
- NCT00173537
- Testing
- for BMPR II study, BMPRII
- Where
- Taiwan
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Pulmonary Vascular Disorder, Pulmonary Artery Hypertension
HA Residents With PVD, Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) With and Without Supplemental Oxygen Therapy (SOT)
To study the effect of SOT in patients with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH) who permanently live >2500m on pulmonary artery…
- Conditions
- Pulmonary Vascular Disorder, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT06084559
- Testing
- Supplemental oxygen therapy
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- University of Zurich
Pulmonary Arterial Hypertension
A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension
This is a multi-center, open-label study for eligible participants who were actively participating in the BPS-314d-MR-PAH-302 double-blind study (NCT01908699) at the time the study was concluded.
- Trial name
- BEAT OLE (NCT03657095)
- Testing
- Esuberaprost
- Where
- 45 sites in United States, Israel
- Volunteers
- 112 people
- Sponsor
- Lung Biotechnology PBC
Pulmonary Vascular Disorder, Primary Pulmonary Hypertension
Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
This is a randomized, double-blind, placebo-controlled, multicenter, multinational study investigating the effect of riociguat (MK-4836) in patients with early pulmonary vascular disease.
- Conditions
- Pulmonary Vascular Disorder, Primary Pulmonary Hypertension, Systemic Sclerosis, Other Systemic Involvement of Connective Tissue
- Trial name
- ESRA (NCT05339087)
- Testing
- Riociguat Oral Tablet
- Where
- 8 sites in Austria, France and 4 more
- Volunteers
- 35 people
- Sponsor
- Heidelberg University
Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Assessment of Blood Coagulation Disorders in Patients With Pulmonary Hypertension
The objective of the present study is to assess blood coagulation disorders in patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension.
- Trial name
- NCT03195543
- Testing
- Platelet function analyzer-100, Light transmission aggregometry, Rotational thromboelastometry
- Where
- Greece
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National and Kapodistrian University of Athens
Pulmonary Artery Hypertension
Is There Intravascular Hemolysis in Patients With Pulmonary Hypertension?
Patients with hemolytic disorders (e.g. sickle cell anemia or thalassemia) are known to develop pulmonary hypertension. Hemolysis is where red blood cells are destroyed and their contents released into the circulation.
- Trial name
- NCT00502398
- Testing
- Blood test
- Where
- Israel
- Volunteers
- healthy volunteers welcome
- Sponsor
- Rabin Medical Center
Severe Pre-eclampsia, Postpartum Condition or Complication
Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia Using Carbetocin Versus Misoprostol
We aim to compare carbetocin with misoprostol for the prevention of postpartum hemorrhage in patients with severe preeclampsia. The primary outcome is postpartum haemorrhage (blood loss of ≥ 500 ml) while our Secondary outcomes…
- Trial name
- carbetocin (NCT02086994)
- Testing
- misoprostol, carbetocin
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- khalid abd aziz mohamed
Pulmonary Artery Hypertension
Impact of Aerobic Training on Sleep Quality and Aerobic Fitness in Male Patients With Pulmonary Artery Hypertension
This study investigated the effect of 12 weeks of aerobic training on sleep quality and aerobic fitness in patients with Pulmonary arterial hypertension(PAH).
- Trial name
- NCT04337671
- Testing
- Moderate intensity aerobic training
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Cairo University
Pulmonary Artery Hypertension
Evaluation of Respiratory Muscle in Patient With Pulmonary Arterial Hypertension
The aim of the study is that evaluation of basic and accessory respiratory muscles and their relationship of six minute walk test in patient with pulmonary arterial hypertension (PAH)
- Trial name
- NCT05056532
- Testing
- patient assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Giresun University
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the…
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo, Healthy Individuals With no Cardiopulmonary Disease
- Trial name
- RARE-PAH (NCT05584722)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Vanderbilt University Medical Center
Myocardial Dysfunction, Endothelial Dysfunction
Bosentan in Myocardium Metabolism and Perfusion Measured by 18F-FDG and 82Rb PET/CT on PAH and CTEPH
The purpose of this study is to assess the effect of bosentan on the myocardial metabolism and the dependent endothelial coronary vasomotoricity in patients presenting a PAH.
- Trial name
- NCT02970851
- Where
- Switzerland
- Volunteers
- 2 people
- Sponsor
- University of Lausanne Hospitals
Pulmonary Artery Hypertension
GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
The primary objective for this trial is to determine the effect of GB002 (seralutinib) on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III.
- Trial name
- NCT04456998
- Testing
- GB002 (seralutinib), Generic Dry Powder Inhaler
- Where
- 63 sites in United States, Australia and 9 more
- Volunteers
- 86 people
- Sponsor
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.